Skip to main content
Fig. 1 | Molecular Cancer

Fig. 1

From: PARP1 expression drives the synergistic antitumor activity of trabectedin and PARP1 inhibitors in sarcoma preclinical models

Fig. 1

Olaparib enhanced trabectedin-induced DNA damage in high-PARP1-expressing cells. FACS analysis of P-H2AX positive cells after 24-h treatment with 0.125 nM trabectedin, 1.25 μM olaparib as single agents and in combination: a representative histograms of DMR cells and b mean quantification of P-H2AX in TC-106 (Ewing), 402.91 (liposarcoma), DMR (leiomyosarcoma), SJSA-1 (osteosarcoma), and HT1080 and SW684 (fibrosarcoma) cells; Y error bars indicate mean ± S.E.M;*** p < 0.001 between combination and both single agents and controls. c Immunofluorescence of P-H2AX in DMR cells treated as in (a and b); d Western blot analysis of PARP1 activity (PARylation) and PARP1 expression after 4-h treatment with 10 nM trabectedin, 20 μM olaparib as single agents and in combination; β-actin was done as loading control; e-f DNA fragmentation obtained after 48-h treatment with 0.125 nM trabectedin, 1.25 μM olaparib as single agents and in combination as revealed by COMET assay: E, representative photomicrographs of COMET tails in 402.91 cells; f Box-plot shows mean comet eccentricity ±25% (boxes) and the 5–95% percentile (whiskers)

Back to article page